Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Solid Biosciences has had another setback.
The biotech announced this morning that its dose-ascending Phase I/II study of its lead gene therapy for Duchenne muscular …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.